CY1119711T1 - Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων - Google Patents

Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων

Info

Publication number
CY1119711T1
CY1119711T1 CY20171100784T CY171100784T CY1119711T1 CY 1119711 T1 CY1119711 T1 CY 1119711T1 CY 20171100784 T CY20171100784 T CY 20171100784T CY 171100784 T CY171100784 T CY 171100784T CY 1119711 T1 CY1119711 T1 CY 1119711T1
Authority
CY
Cyprus
Prior art keywords
diseases
treatment
compound
new union
useful
Prior art date
Application number
CY20171100784T
Other languages
English (en)
Inventor
Javier Blanc
Christel Jeanne Marie Menet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CY1119711T1 publication Critical patent/CY1119711T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Αποκαλύπτεται μια ένωση η οποία έχει τύπο που αντιπροσωπεύεται με τον παρακάτω: (I). Αυτή η ένωση μπορεί να παρασκευάζεται ως φαρμακευτική σύνθεση και μπορεί να χρησιμοποιηθεί για την πρόληψη και τη θεραπεία μιας ποικιλίας καταστάσεων σε θηλαστικά συμπεριλαμβανομένων ανθρώπων, που συμπεριλαμβάνουν ως μη περιοριστικό παράδειγμα, φλεγμονώδεις καταστάσεις, αυτοάνοσες ασθένειες, πολλαπλασιαστικές ασθένειες, απόρριψη μεταμόσχευσης, ασθένειες που περιλαμβάνουν εξασθένηση του ρυθμού ανανέωσης χόνδρου, συγγενείς δυσπλασίες χόνδρου ή/και ασθένειες που συνδυάζονται με υπερέκκριση IL6.
CY20171100784T 2009-06-26 2017-07-24 Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων CY1119711T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25
EP10728648.6A EP2445912B1 (en) 2009-06-26 2010-06-25 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (1)

Publication Number Publication Date
CY1119711T1 true CY1119711T1 (el) 2018-06-27

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100784T CY1119711T1 (el) 2009-06-26 2017-07-24 Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων

Country Status (38)

Country Link
US (2) US8796457B2 (el)
EP (2) EP2792677B1 (el)
JP (1) JP5486084B2 (el)
KR (1) KR101712561B1 (el)
CN (1) CN102459261B (el)
AR (1) AR077221A1 (el)
AU (1) AU2010264635B2 (el)
BR (1) BRPI1014759A2 (el)
CA (1) CA2765988C (el)
CL (1) CL2011003276A1 (el)
CO (1) CO6491039A2 (el)
CR (1) CR20110673A (el)
CY (1) CY1119711T1 (el)
DK (2) DK2445912T3 (el)
DO (1) DOP2011000378A (el)
EA (1) EA020111B1 (el)
ES (2) ES2634325T3 (el)
HK (2) HK1168098A1 (el)
HR (2) HRP20141057T1 (el)
HU (1) HUE034205T2 (el)
IL (1) IL216618A (el)
JO (1) JO3030B1 (el)
LT (1) LT2792677T (el)
MA (1) MA33447B1 (el)
ME (1) ME01916B (el)
MX (1) MX2011013451A (el)
NZ (1) NZ596836A (el)
PE (1) PE20120494A1 (el)
PL (2) PL2792677T3 (el)
PT (2) PT2445912E (el)
RS (1) RS53617B1 (el)
SG (1) SG177359A1 (el)
SI (2) SI2792677T1 (el)
SM (1) SMT201400169B (el)
TW (1) TWI469981B (el)
UY (1) UY32741A (el)
WO (1) WO2010149771A1 (el)
ZA (1) ZA201109502B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP6129155B2 (ja) 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
UY34855A (es) * 2012-06-22 2014-01-31 Galapagos Nv Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella.
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2017013103A (es) * 2015-04-13 2018-01-30 Galapagos Nv Metodos para el tratamiento de trastornos cardiovasculares.
CN109790158B (zh) 2016-07-26 2022-06-24 苏州隆博泰药业有限公司 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
WO2019149244A1 (zh) * 2018-01-31 2019-08-08 南京明德新药研发股份有限公司 Jak抑制剂及其应用
WO2020047029A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
MX2021009242A (es) 2019-01-31 2021-10-26 Sanofi Biotechnology Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica.
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2003101989A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
DE602004001676T2 (de) 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
CN102459261A (zh) 2012-05-16
IL216618A0 (en) 2012-02-29
JP2012530767A (ja) 2012-12-06
EP2445912B1 (en) 2014-08-13
US8796457B2 (en) 2014-08-05
ZA201109502B (en) 2012-09-26
SMT201400169B (it) 2015-01-15
CO6491039A2 (es) 2012-07-31
PE20120494A1 (es) 2012-05-17
US9505754B2 (en) 2016-11-29
HK1168098A1 (en) 2012-12-21
RS53617B1 (en) 2015-04-30
CN102459261B (zh) 2014-11-05
AU2010264635A1 (en) 2011-12-22
SI2792677T1 (sl) 2017-08-31
AR077221A1 (es) 2011-08-10
JO3030B1 (ar) 2016-09-05
PL2445912T3 (pl) 2015-02-27
PT2792677T (pt) 2017-07-06
US20100331359A1 (en) 2010-12-30
ME01916B (me) 2015-05-20
ES2634325T3 (es) 2017-09-27
PT2445912E (pt) 2014-11-07
US20150031671A1 (en) 2015-01-29
WO2010149771A1 (en) 2010-12-29
SI2445912T1 (sl) 2014-12-31
AU2010264635B2 (en) 2015-05-07
EA020111B1 (ru) 2014-08-29
KR101712561B1 (ko) 2017-03-06
CR20110673A (es) 2012-02-09
NZ596836A (en) 2013-02-22
CA2765988A1 (en) 2010-12-29
HK1202537A1 (en) 2015-10-02
TWI469981B (zh) 2015-01-21
TW201103937A (en) 2011-02-01
ES2519170T3 (es) 2014-11-06
MA33447B1 (fr) 2012-07-03
IL216618A (en) 2014-09-30
HUE034205T2 (en) 2018-01-29
BRPI1014759A2 (pt) 2016-04-19
HRP20141057T1 (en) 2015-03-13
CA2765988C (en) 2017-08-29
HRP20171024T1 (hr) 2017-10-06
DK2792677T3 (en) 2017-07-10
CL2011003276A1 (es) 2012-08-31
EP2445912A1 (en) 2012-05-02
UY32741A (es) 2011-01-31
SG177359A1 (en) 2012-02-28
EA201270076A1 (ru) 2012-08-30
KR20120059487A (ko) 2012-06-08
EP2792677A1 (en) 2014-10-22
DOP2011000378A (es) 2012-02-15
DK2445912T3 (da) 2014-11-10
PL2792677T3 (pl) 2017-09-29
LT2792677T (lt) 2017-07-25
JP5486084B2 (ja) 2014-05-07
EP2792677B1 (en) 2017-04-26
MX2011013451A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
CY1119711T1 (el) Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1119214T1 (el) 5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CY1123690T1 (el) Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
IN2012DN03883A (el)
EA201270149A1 (ru) Ингибиторы bace
EA201100447A1 (ru) Органические соединения
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX355653B (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201290305A1 (ru) Производные трициклического пиразоламина
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201590071A1 (ru) Аминотриазолопиридин для применения в лечении воспаления и его фармацевтические композиции
MX2012002641A (es) Inhibidores de cinasa janus (jak).
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
IN2012DN03846A (el)
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique